Physician profile

Andrew Reese

Family Medicine · Waterloo, NY

NPI 1861489312

$6,973.27

in general payments reported to CMS, 2019-2025

43 companies · $1,063 in 2025

The $1,063 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$2,819.31

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Astrazeneca Pharmaceuticals LP $1,188.91 2019-2025 Airsupra, Farxiga, Breztri
Pfizer INC. $957.51 2019-2025
Novo Nordisk INC $601.72 2019-2025 Rybelsus, Ozempic, Wegovy
Glaxosmithkline, LLC. $521.35 2019-2025 Trelegy Ellipta, Shingrix
Janssen Pharmaceuticals, INC $252.76 2019-2023 Xarelto
Salix Pharmaceuticals, A Division of Bausch Health US, LLC $235.77 2019-2025 Xifaxan, Trulance
Abbvie INC. $231.75 2019-2025
Exact Sciences Corporation $231.05 2023-2025 Cologuard Collection Kit, The Cologuard Plus Collection Kit
Amarin Pharma, INC. $223.96 2019-2021
Abbott Laboratories $208.41 2019-2025 Freestyle Libre 3
Lilly USA, LLC $208.33 2019-2024 Zepbound, Mounjaro
Merck Sharp & Dohme LLC $200.82 2019-2025 Gardasil 9, Vaxelis, Rotateq
Amgen INC. $197.62 2019-2024 Otezla, Repatha, Evenity
Astellas Pharma US INC $183.30 2019-2024 Veozah
Bayer Healthcare Pharmaceuticals INC. $181.29 2023-2025
Show all 43 companies
CompanyGeneral paymentsYearsTop products
Novartis Pharmaceuticals Corporation $164.88 2019-2023
Takeda Pharmaceuticals U.S.A., INC. $134.99 2019-2021
Ibsa Pharma INC. $116.08 2019-2025 Tirosint, Licart, Flector
Boehringer Ingelheim Pharmaceuticals, INC. $113.12 2019-2023 Spiriva Respimat, Stiolto Respimat
Allergan, INC. $98.55 2019-2020
Sanofi-Aventis U.S. LLC $83.10 2019-2020
Teva Pharmaceuticals USA, INC. $76.28 2019-2020
Phathom Pharmaceuticals, INC. $66.56 2024-2025 Voquezna
Sumitomo Pharma America, INC. $58.30 2024-2025 Gemtesa
Supernus Pharmaceuticals, INC. $48.94 2020
E.R. Squibb & Sons, L.L.C. $48.15 2021-2023 Eliquis
Kowa Pharmaceuticals America, INC. $31.08 2019
Insulet Corporation $29.58 2024 Omnipod
Collegium Pharmaceutical, INC. $29.17 2021
Eisai INC. $26.53 2020
Alk-Abello, INC $25.26 2025 Neffy, Odactra, Grastek
Ucb, INC. $21.80 2024 Nayzilam
Sunovion Pharmaceuticals INC. $21.39 2020
Ars Pharmaceuticals Operations, INC. $20.43 2025 Neffy
Corium, LLC $20.39 2024 Azstarys
Otsuka America Pharmaceutical, INC. $16.86 2021
Ironwood Pharmaceuticals, INC $16.36 2021
Optinose US, INC. $15.60 2021
Esperion Therapeutics, INC. $14.60 2021
Inspire Medical Systems, INC. $13.61 2025 Inspire
Biohaven Pharmaceuticals, INC. $12.43 2021
Ironshore Pharmaceuticals INC. $12.36 2019
Horizon Therapeutics Plc $12.32 2020

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Andrew Reese

$6,973.27

in general payments reported 2019-2025

Years
2019-2025
Top company
Astrazeneca Pharmaceuticals LP
Context
The $1,063 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).

https://glasscript.com/doctor/558474/andrew-reese

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.